Business, energy, technology, markets and global industry news from Business News Today

Pharma & Biotech

PharmaDeviceNews Pharma & Biotech
A clinician examines atopic dermatitis symptoms as Bambusa Therapeutics reports preliminary proof-of-concept results for investigational bispecific antibody BBT001. Representative image.
Pharma & Biotech

Could BBT001 quarterly dosing differentiate Bambusa in the atopic dermatitis biologics market?

Bambusa’s BBT001 produced an early atopic dermatitis signal, but larger trials must confirm safety, durability and quarterly dosing.

Read More
Laboratory research into next-generation obesity treatments highlights Ascletis Pharma Inc.’s preclinical ASC37 triple peptide agonist, which produced greater weight loss than tirzepatide in a diet-induced obese mouse study. Representative image.
Pharma & Biotech

Can Ascletis ASC37 become a once-monthly triple agonist for obesity?

Ascletis says ASC37 beat tirzepatide in obese mice, but human dosing, safety and durability remain untested ahead of a planned U.S. IND.

Read More
ARTHEx Biotech’s ATX-01 preclinical research examines whether systemic RNA therapy can reach the brain and improve DM1-related molecular and behavioral abnormalities. Representative image.
Pharma & Biotech

ARTHEx Biotech reports ATX-01 brain activity in preclinical myotonic dystrophy study

ARTHEx Biotech reports peer-reviewed preclinical evidence that ATX-01 reaches the brain and improves DM1-related behavior in mice.

Read More
Lundbeck’s investigational orexin 2 receptor agonist Lu AH69593 has received FDA Fast Track designation as competition intensifies to develop new narcolepsy treatments targeting sleep-wake regulation. Representative image.
Pharma & Biotech

Lundbeck has FDA Fast Track status for Lu AH69593, but can it catch the narcolepsy orexin leaders?

Lundbeck’s Lu AH69593 gains FDA Fast Track status, but its Phase 1 narcolepsy programme enters an increasingly competitive orexin field.

Read More
A woman experiencing menopause-related fatigue and discomfort, as Bonerge Lifescience launches a clinical study evaluating EquoYouth S-equol for potential menopause symptom relief. Representative image.
Pharma & Biotech

Can Bonerge’s EquoYouth S-equol study strengthen evidence for menopause relief?

Bonerge Lifescience begins an EquoYouth S-equol menopause study as researchers test whether new data can strengthen a contested supplement case.

Read More
Harbour BioMed and Sinopharm’s strategic R&D consortium aims to connect antibody discovery, biologics development and manufacturing across oncology and inflammatory diseases. Representative image.
Pharma & Biotech

Harbour BioMed’s Sinopharm alliance spans the entire drug lifecycle, but its first real test has not been named

Harbour BioMed and Sinopharm form a biologics R&D consortium spanning antibody discovery, clinical development, manufacturing and commercialisation.

Read More
Eli Lilly’s investigational retatrutide delivered significant weight loss and A1C improvements in the Phase 3 TRIUMPH-2 and TRIUMPH-3 obesity trials. Representative image.
Pharma & Biotech

Retatrutide TRIUMPH-3 trial advances Eli Lilly’s 2027 FDA filing plan

Eli Lilly’s retatrutide delivered up to 22.6% weight loss in two Phase 3 trials as a 2027 FDA filing moves closer.

Read More
Evoworks Bio’s BARDA-backed VANGUARD project will evaluate whether modular cell-culture technology can enable faster, scalable production of critical antibody biologics. Representative image.
Pharma & Biotech

Evoworks Bio wins BARDA-backed VANGUARD funding for EvoNode biologics production study

See how Evoworks Bio’s BARDA-backed EvoNode project could test faster, modular antibody production for United States health security.

Read More
Canton Strategic Holdings’ $3.5 million seller-financed sale of Gravitas Life Sciences separates its clinical-stage biotechnology pipeline from its Canton Network-focused digital asset strategy. Representative image.
Pharma & Biotech

Canton Strategic left biotech behind, but its $3.5m Gravitas deal is not a cash windfall

Canton Strategic sells Gravitas Life Sciences for a $3.5 million seller note, sharpening its Canton Network focus as biotech risks shift.

Read More
Accord BioPharma’s U.S. launch of Osvyrti and Jubereq brings two interchangeable denosumab biosimilars into the increasingly competitive osteoporosis and oncology-support market. Representative image.
Pharma & Biotech

Jubereq launch: Accord BioPharma challenges Xgeva in cancer-related bone complications

Accord BioPharma launches Osvyrti and Jubereq as interchangeable denosumab biosimilars, testing price, payer access and provider adoption.

Read More